Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma

被引:5
|
作者
Zhao, Tiesuo [1 ,2 ,3 ]
Wei, Pengkun [1 ,2 ,4 ]
Zhang, Congli [1 ,2 ]
Zhou, Shijie [1 ,2 ]
Liang, Lirui [1 ,2 ]
Guo, Shuoshuo [1 ,2 ]
Yin, Zhinan [5 ]
Cheng, Sichang [1 ,2 ]
Gan, Zerui [1 ,2 ]
Xia, Yuanling [1 ,2 ]
Zhang, Yongxi [6 ]
Guo, Sheng [1 ,2 ]
Zhong, Jiateng [2 ]
Yang, Zishan [1 ,2 ]
Tu, Fei [2 ]
Wang, Qianqing [7 ,8 ]
Bai, Jin [7 ,8 ]
Ren, Feng [3 ]
Feng, Zhiwei [1 ,2 ]
Jia, Huijie [2 ]
机构
[1] Xinxiang Med Univ, Sch Basic Med Sci, Dept Immunol, Xinxiang, Peoples R China
[2] Xinxiang Med Univ, Xinxiang Engn Technol Res Ctr Immune Checkpoint Dr, Xinxiang, Peoples R China
[3] Xinxiang Med Univ, Henan Int Joint Lab Immun & Targeted Therapy Liver, Xinxiang, Peoples R China
[4] Zhengzhou Univ, Zhengzhou Cent Hosp, Zhengzhou, Peoples R China
[5] Jinan Univ, Biomed Translat Res Inst, Fac Med Sci, Guangzhou, Peoples R China
[6] Xinxiang Med Univ, Affiliated Hosp 3, Dept Oncol, Xinxiang, Peoples R China
[7] Xinxiang Cent Hosp, Dept Gynecol, Xinxiang, Peoples R China
[8] Xinxiang Med Univ, Clin Coll 4, Xinxiang, Peoples R China
来源
ELIFE | 2024年 / 12卷
关键词
hepatocellular carcinoma; PD-L1; radiotherapy; cancer immunotherapy; Mouse;
D O I
10.7554/eLife.90911
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Radiation therapy is a primary treatment for hepatocellular carcinoma (HCC), but its effectiveness can be diminished by various factors. The over-expression of PD-L1 has been identified as a critical reason for radiotherapy resistance. Previous studies have demonstrated that nifuroxazide exerts antitumor activity by damaging the Stat3 pathway, but its efficacy against PD-L1 has remained unclear. In this study, we investigated whether nifuroxazide could enhance the efficacy of radiotherapy in HCC by reducing PD-L1 expression. Our results showed that nifuroxazide significantly increased the sensitivity of tumor cells to radiation therapy by inhibiting cell proliferation and migration while increasing apoptosis in vitro. Additionally, nifuroxazide attenuated the up-regulation of PD-L1 expression induced by irradiation, which may be associated with increased degradation of PD-L1 through the ubiquitination-proteasome pathway. Furthermore, nifuroxazide greatly enhanced the efficacy of radiation therapy in H22-bearing mice by inhibiting tumor growth, improving survival, boosting the activation of T lymphocytes, and decelerating the ratios of Treg cells in spleens. Importantly, nifuroxazide limited the increased expression of PD-L1 in tumor tissues induced by radiation therapy. This study confirms, for the first time, that nifuroxazide can augment PD-L1 degradation to improve the efficacy of radiation therapy in HCC-bearing mice.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] PD-L1 expression in hepatocellular carcinoma
    Kanda, Hiroaki
    Mahmut, Yasin
    Shigematsu, Yasuyuki
    Sugiura, Yoshiya
    Yamamoto, Noriko
    Ishikawa, Yuichi
    CANCER SCIENCE, 2018, 109 : 1123 - 1123
  • [2] Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma
    Guo, Rui
    Rao, Pan-guo
    Liao, Bao-zhen
    Luo, Xin
    Yang, Wen-wen
    Lei, Xing-heng
    Ye, Jun-ming
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [3] Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma
    Gao, Zi-Xuan
    Zhang, Zhan-Sheng
    Qin, Jia
    Zhang, Ming -Zhu
    Cao, Jin-Lan
    Li, Ying-Ying
    Wang, Meng-Qing
    Fang, Dong
    Xie, Song-Qiang
    PHYTOMEDICINE, 2023, 112
  • [4] The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma
    Xu, Hao
    Liang, Xiao-Lu
    Liu, Xiao-Guang
    Chen, Nian-Ping
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (03) : 1132 - +
  • [5] PD-L1 Expression is an Unfavorable Prognostic Factor in Hepatocellular Carcinoma
    Baek, M.
    Jung, H.
    Ahn, T.
    Park, S.
    Bae, S.
    Jung, D.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S111 - S111
  • [6] Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma
    Yu-Yun Shao
    Han-Yu Wang
    Hung-Wei Hsu
    Rita Robin Wo
    Ann-Lii Cheng
    Chih-Hung Hsu
    Biology Direct, 20 (1)
  • [7] PD-L1 expression on circulating tumor cells in patients with hepatocellular carcinoma
    Kim, Hee Yeon
    Kim, Chang Wook
    Kim, Sungkeun
    Kim, Ji Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 409 - 409
  • [8] A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma
    Shi, Lei
    Zhang, Shu-Jun
    Chen, Jun
    Lu, Shi-Xun
    Fan, Xin-Juan
    Tong, Joanna Hung-Man
    Chow, Chit
    Tin, Edith Ka-Yee
    Chan, Stephen Lam
    Chong, Charing Ching-Ning
    Lai, Paul Bo-San
    To, Ka-Fai
    Wong, Nathalie
    Chan, Anthony Wing-Hung
    MODERN PATHOLOGY, 2019, 32 (11) : 1646 - 1656
  • [9] Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells
    Xing, Shijiang
    Chen, Shengli
    Yang, Xinglong
    Huang, Weiyi
    JOURNAL OF BUON, 2020, 25 (04): : 1875 - 1882
  • [10] Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression
    Gao, Meng
    Zhang, Dongjian
    Jiang, Cuihua
    Jin, Qiaomei
    Zhang, Jian
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 166